Accelerating Biomarker-Driven Therapy & Clinical-Trial Enrollment with Rapid Front-Line NGS

• Learn how rapid front-line targeted NGS enables earlier detection of actionable biomarkers, supporting timely precision oncology treatment decisions and companion diagnostic strategies 
• Discover best practices for developing, validating, and implementing a rapid targeted NGS assay that complements comprehensive genomic profiling while accelerating biomarker identification
• Explore how rapid genomic insights can expedite biomarker-driven clinical trial enrollment, improve access to targeted therapies, and support pharmaceutical and diagnostic partners developing companion diagnostics
• See how optimized workflows using the Illumina MiSeq™ i100 Series and Hamilton STARlet can reduce NGS turnaround times, helping bring biomarker-guided therapies and CDx solutions to patients faster

Speakers:

Mark Ewalt

Associate Medical Director, Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service

Memorial Sloan Kettering Cancer Center